{"id":"chf5993-pmdi-with-hfa-134a","safety":{"commonSideEffects":[{"rate":"null","effect":"Oral thrush"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Cough"}]},"_chembl":{"chemblId":"CHEMBL2104432","moleculeType":"Small molecule","molecularWeight":"102.03"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The HFA-134a propellant is used to deliver the corticosteroid to the lungs.","oneSentence":"CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:26:20.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of COPD"}]},"trialDetails":[{"nctId":"NCT07301736","phase":"PHASE2","title":"Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-12-17","conditions":"Asthma","enrollment":780},{"nctId":"NCT06264674","phase":"PHASE3","title":"Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-27","conditions":"Asthma","enrollment":836},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":61,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}